[go: up one dir, main page]

ATE342509T1 - Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau - Google Patents

Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Info

Publication number
ATE342509T1
ATE342509T1 AT01909655T AT01909655T ATE342509T1 AT E342509 T1 ATE342509 T1 AT E342509T1 AT 01909655 T AT01909655 T AT 01909655T AT 01909655 T AT01909655 T AT 01909655T AT E342509 T1 ATE342509 T1 AT E342509T1
Authority
AT
Austria
Prior art keywords
tau
phospho
diagnosis
tauopathies
ratio
Prior art date
Application number
AT01909655T
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE342509T1 publication Critical patent/ATE342509T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
AT01909655T 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau ATE342509T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00870008 2000-01-24
US17839100P 2000-01-27 2000-01-27
EP00870280 2000-11-22

Publications (1)

Publication Number Publication Date
ATE342509T1 true ATE342509T1 (de) 2006-11-15

Family

ID=27223742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909655T ATE342509T1 (de) 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Country Status (13)

Country Link
US (2) US6680173B2 (de)
EP (1) EP1250600B1 (de)
JP (1) JP5247963B2 (de)
AT (1) ATE342509T1 (de)
AU (1) AU777837B2 (de)
BR (1) BR0107851A (de)
CA (1) CA2397991C (de)
CY (1) CY1107993T1 (de)
DE (2) DE1250600T1 (de)
DK (1) DK1250600T3 (de)
ES (1) ES2274869T3 (de)
HK (1) HK1048513B (de)
WO (1) WO2001055725A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP4681175B2 (ja) * 2001-09-28 2011-05-11 三菱化学メディエンス株式会社 播種性血管内凝固症候群及びその発症前段階を検出する方法
WO2004016655A1 (ja) * 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
EP1606404A4 (de) * 2003-03-12 2006-04-12 Assay Designs Inc Phosphokinasetest
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
AU2009248914A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
EP3139174B1 (de) 2009-09-24 2018-11-07 Etienne Baulieu Fkbp52-tau-interaktion als neuartiges therapeutisches target zur behandlung von neurologischen erkrankungen im zusammenhang mit tau-dysfunktion
WO2011109112A2 (en) * 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
US20130052669A1 (en) * 2010-04-30 2013-02-28 Amanda G. Paulovich Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
ES2775192T3 (es) * 2012-08-16 2020-07-24 Ipierian Inc Procedimientos de tratamiento de una tauopatía
WO2014039630A2 (en) 2012-09-05 2014-03-13 Emory University Diagnostic testing in dementia and methods related thereto
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
HUE050485T2 (hu) 2013-06-10 2020-12-28 Ipierian Inc Tauopathia kezelési módszerei
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
EP3104870A4 (de) 2014-02-14 2017-09-13 Ipierian, Inc. Tau-peptide, anti-tau-antikörper und verfahren zur verwendung davon
CN106605146B (zh) * 2014-04-08 2020-07-28 佛罗里达大学研究基金会有限公司 用于中枢神经系统的急性、亚急性和慢性创伤性损伤的蛋白质标志物
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
DE102014013571A1 (de) * 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
US20180050097A1 (en) * 2015-03-25 2018-02-22 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
KR102033776B1 (ko) * 2017-10-31 2019-10-17 가천대학교 산학협력단 타우 단백질의 발현수준을 측정하는 제제를 포함하는 알츠하이머 중증도 진단용 조성물 및 이를 이용한 알츠하이머 중증도의 진단방법
CA3093200A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20220018856A1 (en) * 2018-11-22 2022-01-20 Fujirebio Inc. Antibody conjugate
JP2022527087A (ja) * 2019-03-28 2022-05-30 ハー・ルンドベック・アクチエゼルスカベット タウオパチーを診断するためのｐＳ３９６アッセイの使用
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
KR102905634B1 (ko) * 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
MX2022009607A (es) * 2020-02-05 2022-09-02 Sumitomo Pharma Co Ltd Agente de determinacion y metodo de determinacion de taupatia y enfermedades relacionadas con la demencia.
KR20240134175A (ko) * 2022-01-12 2024-09-06 지틴벤트 리미티드 샘플에서 타우(tau) 단백질 단편을 검출하기 위한 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600951A4 (en) * 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1994013795A1 (en) * 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
DE69434811T2 (de) * 1993-12-21 2007-03-01 Innogenetics N.V. Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
CA2195672A1 (en) * 1994-07-29 1996-02-15 Eugeen Vanmechelen Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU4322999A (en) * 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies

Also Published As

Publication number Publication date
EP1250600A2 (de) 2002-10-23
DE60123752D1 (de) 2006-11-23
US20040091942A1 (en) 2004-05-13
HK1048513B (en) 2007-12-07
CY1107993T1 (el) 2013-09-04
CA2397991A1 (en) 2001-08-02
WO2001055725A3 (en) 2001-12-20
HK1048513A1 (en) 2003-04-04
DK1250600T3 (da) 2007-02-05
BR0107851A (pt) 2002-10-29
AU3731901A (en) 2001-08-07
WO2001055725A2 (en) 2001-08-02
US7387879B2 (en) 2008-06-17
US6680173B2 (en) 2004-01-20
DE1250600T1 (de) 2003-03-06
DE60123752T2 (de) 2007-08-23
EP1250600B1 (de) 2006-10-11
CA2397991C (en) 2017-10-24
AU777837B2 (en) 2004-11-04
US20030194742A1 (en) 2003-10-16
ES2274869T3 (es) 2007-06-01
JP2003521499A (ja) 2003-07-15
JP5247963B2 (ja) 2013-07-24

Similar Documents

Publication Publication Date Title
ATE342509T1 (de) Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
NO973444L (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
ATE394658T1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
ATE406578T1 (de) Candida-nachweis
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
ATE312349T1 (de) Differentielle diagnose von neurodegeneration
WO2003008933A3 (en) Test strip for a lateral flow assay
BR9710836A (pt) Ensaio de analitos usando marcas em partìculas
ITTO20010411A0 (it) Metodo e dispositivo per l'esecuzione di test e saggi ad alta processivita' ed alto valore biologico su cellule e/o composti.
WO2002046746A3 (en) Method for detection of vitamin d metabolites
EP1461061A4 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von krankheiten und zuständen im zusammenhang mit chemokine-rezeptoren
ATE319094T1 (de) Diagnose von pre-eclampsia
KR950018482A (ko) 혈소판 응집 측정방법
ES2068599T3 (es) Procedimiento de reduccion de interferencias en un dosificado por fluorescencia.
WO2003084384A3 (en) Diagnosis of flavivirus infection
WO2002059600A3 (en) Analyte detection
WO2000026251A3 (en) A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
EP1281083A4 (de) Verfahren zur erkennung von entzündungen und entzündungsbedingungen
DE60126991D1 (de) Verfahren ZUR DIAGNOSE VON SCHIZOPHRENIE
DE60217079D1 (de) Nachweis und quantifizierung von cripto-1
WO2004029216A3 (en) Diagnosis of invasive mold infection
DE60236849D1 (de) Diagnose von atherosclerose
EP1731913A3 (de) Verfahren und Zusammensetzungen zur Bestimmung des Lipidperoxidierungsgehaltes in oxidativen Stress-Syndromen und Krankheiten
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
WO2002050543A3 (en) Free analyte detection system

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250600

Country of ref document: EP